

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/509,502	09/28/2004	Gerd Ascher	IB/G-32413A	4016
1095	7590 12/13/2006		EXAMINER	
NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080			CHONG, YONG SOO	
			ART UNIT	PAPER NUMBER
			1617	

DATE MAILED: 12/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/509,502	ASCHER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Yong S. Chong	1617			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
 Responsive to communication(s) filed on 16 October 2006. This action is FINAL. 2b) This action is non-final. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. 					
Disposition of Claims					
4) Claim(s) 2-18 is/are pending in the application. 4a) Of the above claim(s) 6-17 is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 2-5 and 18 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119 12) △ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) △ All b) ☐ Some * c) ☐ None of: 1. △ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

Page 2

DETAILED ACTION

Status of the Application

This Office Action is in response to applicant's arguments filed on 10/16/2006.

Claim(s) 1 has been cancelled. Claim(s) 2-17 are pending. Claim(s) 5 has been amended. Claim(s) 6-17 have been withdrawn. Claim(s) 2-5, 18 are examined herein.

Applicant's amendments have rendered the 112 rejection moot, therefore hereby withdrawn. Applicant's arguments have been fully considered but found not persuasive. The 103(a) rejection of the last Office Action is maintained for reasons of record and repeated below for Applicant's convenience.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in Graham vs John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Application/Control Number: 10/509,502

Art Unit: 1617

Claims 2-5, 18 are rejected under 35 U.S.C. 103(a) as being obvious over Ferguson et al. (US Patent Application 2005/0159377 A1) in view of Egger et al. (US Patent 4,278,674).

The instant claims are directed to a method of treating Mycobacterium tuberculosis with pleuromutilins, specifically 1-Tiamulin.

Ferguson et al. teach that pleuromutilins possess antimicrobial activity (section 0002). Moreover, Ferguson et al. disclose that pleuromutilins have activity over a wide range of bacteria including *Mycobacterium tuberculosis* (section 0113 and 0114).

However, Ferguson et al. fail to disclose specifically 1-Tiamulin.

Egger et al. disclose a new class of pleuromutilins with antibacterial effects (abstract). A preferred pleuromutilin is 14-Desoxy-14-[(2-dimethylaminooethyl)mercaptoacetoxy]mutilin otherwise known as 1-Tiamulin (example 1).

Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to substitute 1-Tiamulin as taught by Egger et al. for the pleuromutilin as taught by Ferguson et al.

A person of ordinary skill in the art would have been motivated to make this substitution because: (1) both Ferguson and Egger et al. teach the use of pleuromutilin, (2) both Ferguson and Egger et al. teach the art equivalency of pleuromutilins since both are disclosed to have antimicrobial properties, (3) thus there is a reasonable expectancy of successfully treating Mycobacterium tuberculosis with 1-Tiamulin.

Art Unit: 1617

Response to Arguments

Applicant argues that the conclusion of obviousness was based on impermissible hindsight because Ferguson et al. discloses at least 45 different genus types of microorganisms which pleuromutilins have activity over. Applicant argues that Ferguson et al. simply fail to specifically teach anywhere in the reference that pleuromutilins would have, or would be expected to have, activity over *Myobacteria* in particular. Therefore, Applicant argues that the Examiner has applied improper obvious to try rationale by trying each of the numerous possible choices until one possibly arrived at the successful result.

This is not persuasive because Ferguson et al. clearly discloses the general teaching that pleuromutilins are a class of protein synthesis inhibitors, which possess antimicrobial activity. This wide range of antimicrobial activity encompasses bacteria such as the disclosed *Mycobacterium tuberculosis*. Moreover, Egger et al. disclose a new class of pleuromutilins, for example 1-Tiamulin, with possesses antibacterial effects. Accordingly, the skilled artisan would have had a reasonable expectation of success in treating *Mycobacterium tuberculosis* with pleuromutilins, such as 1-Tiamulin.

Examiner notes that this is a typical genus/species situation. Once a *prima facie* case of obviousness is established, the burden is shifted to the Applicant for objective evidence for nonobviousness. See MPEP 2144.08.

In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon

Art Unit: 1617

hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971).

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong S. Chong whose telephone number is (571)-272-8513. The examiner can normally be reached on M-F, 9-6.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, SREENI PADMANABHAN can be reached on (571)-272-0629. The fax

Application/Control Number: 10/509,502 Page 6

Art Unit: 1617

phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

YSC

SREENI PADMANABHAN SUPERVISORY PATENT EXAMINER